Magungunan Trazhenta: umarnin, sake dubawa game da masu ciwon sukari da tsada

Trazhenta wata sabuwar magani ce da za ta rage yawan sukarin jini a cikin cutar sankara, a Rasha an yi mata rajista a shekarar 2012. Abunda ke aiki na Trazhenta, linagliptin, ya kasance ɗaya daga cikin azuzuwan mafi aminci na wakilan hypoglycemic - DPP-4 inhibitors. An yarda da su sosai, ba su da wata illa, kuma kusan ba sa haifar da ƙin jini.

Wani trazenta a cikin rukuni na kwayoyi tare da kusanci yana tsaye baya. Linagliptin yana da ingantaccen aiki, don haka a cikin kwamfutar hannu kawai 5 MG na wannan abun. Bugu da kari, kodan da hanta ba su shiga cikin keɓantarsa ​​ba, wanda ke nufin cewa masu ciwon sukari tare da ƙarancin waɗannan gabobin na iya daukar Trazhentu.

Alamu don amfani

Umarnin ya ba da izinin Trazent don a keɓe shi ga masu ciwon sukari masu fama da cutar 2 kawai. A matsayinka na mai mulki, magani ne na 2, wato, an gabatar dashi cikin tsarin magani lokacin gyaran abinci, motsa jiki, metformin a cikin mafi kyawun ko mafi girman suturar da aka bayar don samar da isasshen diyya ga masu ciwon sukari.

Alamu don shigowa:

1. Ana iya tsara Trazhent a matsayin kawai hypoglycemic lokacin da metformin ba ta da haƙuri ko an hana amfani da shi.
2. Ana iya amfani dashi azaman wani ɓangare na ingantaccen magani tare da abubuwan da suka samo asali na sulfonylurea, metformin, glitazones, insulin.
3. Hadarin cututtukan hypoglycemia lokacin amfani da Trazhenta kadan ne, sabili da haka, an fi son magunguna ga marasa lafiya da ke haifar da haɗarin sukari mai haɗari.
4. Ofaya daga cikin mummunan sakamako kuma na kowa sakamakon ciwon sukari shine lalacewa ta hanyar aiki na yara - nephropathy tare da haɓaka haɓakar koda. Zuwa wasu lokuta, wannan rikitarwa yana faruwa a cikin 40% na masu ciwon sukari, yawanci yakan fara asymptomatic. Thearfafa tasirin rikice-rikice yana buƙatar gyara tsarin kulawa, tunda yawancin kwayoyi suna cire kodan. Marasa lafiya dole su soke metformin da vildagliptin, rage sashi na acarbose, sulfonylurea, saxagliptin, sitagliptin. A wajen likita, glitazones, glinids da Trazhent kawai suke.
5. Akai-akai tsakanin marasa lafiya da ciwon sukari da kuma nakasa aikin hanta, musamman ma hepatosis mai. A wannan yanayin, Trazhenta ita ce kawai magani daga masu hanawar DPP4, wanda umarnin ya ba da damar amfani ba tare da ƙuntatawa ba. Wannan gaskiya ne musamman ga tsofaffi marasa lafiya da ke da haɗarin hauhawar jini.

Fara daga Trazhenta, zaku iya tsammanin cewa haemoglobin mai narkewa zai ragu da kusan 0.7%. A hade tare da metformin, sakamakon ya fi kyau - kusan 0.95%. Shaidun likitocin sun nuna cewa maganin yana daidai da inganci a cikin marasa lafiya waɗanda kawai ke gano cututtukan sukari mellitus kuma tare da ƙwarewar cutar fiye da shekaru 5. Nazarin da aka gudanar a cikin shekaru 2 sun tabbatar da cewa tasiri na maganin Trazent ba ya raguwa da lokaci.

Ciwon sukari da hauhawar jini zai zama abin da ya wuce

• Normalization na sukari -95%
• Cirewa kan jijiyoyin mara wuya - 70%
• Cire zuciyar mai karfin zuciya -90%
• Rabu da cutar hawan jini - 92%
• Increasearuwar kuzarin rana, inganta bacci da dare -97%

Ta yaya miyagun ƙwayoyi ke aiki?

Kwayoyin halitta na ciki suna da hannu kai tsaye don rage glucose zuwa matakin kimiyyar lissafi. Theiraƙƙarin hankalinsu yana ƙaruwa yayin shigar da glucose a cikin tasoshin. Sakamakon aikin incretins shine karuwa a cikin aikin insulin, raguwa a cikin glucagon, wanda ke haifar da raguwa a cikin glycemia.

Ana lalata tsoffin hanzari ta hanzarin enzymes na musamman DPP-4. Magungunan Trazhenta suna da ikon ɗaure wa waɗannan enzymes, rage jinkirin ayyukansu, sabili da haka, tsawanta rayuwar incretins da ƙara ƙaddamar da insulin a cikin jini a cikin ciwon sukari.

Amfani mara izini na Trazhenta shine cire abu mai aiki akasari tare da bile ta hanjin hanji. Dangane da umarnin, ba fiye da 5% na linagliptin da ke cikin fitsari ba, har ƙasa da metabolized a cikin hanta.

Dangane da masu ciwon sukari, amfanin Trazhenty sune:

• shan miyagun ƙwayoyi sau ɗaya a rana;
• an tsara duk marasa lafiya sashi daya;
• ba a buƙatar daidaita sashi na cututtukan cututtukan hanta da koda;
• babu ƙarin gwaje-gwaje da ake buƙata don nada Trazenti;
• maganin ba mai guba bane ga hanta;
• sashi ba ya canzawa yayin shan Trazhenty tare da wasu kwayoyi;
• hulɗa da magani na linagliptin kusan bai rage tasiri ba. Ga masu ciwon sukari, wannan gaskiyane, tunda dole sai sun sha kwayoyi da yawa a lokaci guda.

Sashi da tsari sashi

Trazhenta na miyagun ƙwayoyi yana samuwa a cikin nau'ikan allunan a cikin launin launi mai zurfi. Don kare karɓaɓɓiyar jabu, a gefe ɗaya ɓangaren alamar kasuwancin masana'anta, an tura gungun kamfanonin Beringer Ingelheim, a ɗayan - alamun D5.

Kwamfutar hannu tana cikin kwalliyar fim, ba a bayar da rabo ba a cikin sassan. A cikin kunshin da aka sayar a Rasha, allunan 30 (3 blisters of 10 inji mai kwakwalwa). Kowane kwamfutar hannu na Trazhenta ya ƙunshi linigliptin 5 MG, sitaci, mannitol, magnesium stearate, dyes. Umarnin don amfani yana samar da cikakken jerin abubuwan taimako.

Umarnin don amfani

Game da ciwon sukari mellitus, shawarar da aka bayar na yau da kullun shine 1 kwamfutar hannu. Kuna iya sha shi a kowane lokaci mafi dacewa, ba tare da haɗin abinci tare da abinci ba. Idan an ba da magani na Trezhent ban da metformin, ƙwayar ta ragu ba ta canzawa.

Idan ka rasa kwaya, zaka iya ɗaukar ta a wannan rana. An haramta shan Trazhent cikin kashi biyu, koda kuwa an rasa liyafar a ranar da ta gabata.

Lokacin da aka yi amfani da shi tare da glimepiride, glibenclamide, gliclazide da analogues, hypoglycemia yana yiwuwa. Don hana su, Trazhenta ya bugu kamar dā, kuma ana rage kashi ɗaya na sauran kwayoyi har sai an sami isasshen ƙwayar cuta. A cikin mafi ƙarancin kwanaki uku daga farkon farawar Trazhenta, ana buƙatar sarrafa glucose mai sauri, tunda tasirin maganin yana haɓaka hankali. Dangane da sake dubawa, bayan zabar sabon kashi, yawan ci gaba da tsananin ƙarfin jini ya zama ƙasa da lokacin farawa tare da Trazhenta.

Hanyoyin hulɗa na miyagun ƙwayoyi dangane da umarnin:

A cikin wasu kwayoyi, ba a sami ma'amala da Trazhenta ba.

Me zai iya cutar da

Ana iya kulawa da sakamako masu illa na Trazenti yayin gwajin asibiti da kuma bayan siyar da miyagun ƙwayoyi. Dangane da sakamakon da suka samu, Trazhenta ya kasance ɗayan amintattun amincin jini. Rashin haɗarin illa da ke tattare da shan magungunan anƙalla ne.

Abin sha'awa shine, a cikin rukuni na masu ciwon sukari waɗanda suka karɓi placebo (allunan ba tare da wani abu mai aiki ba), 4.3% sun ƙi magani, dalilin shine alamun sakamako masu illa. A cikin ƙungiyar da ta ɗauki Trazhent, waɗannan marasa lafiya ba su da ƙasa, 3.4%.

A cikin umarnin don amfani, duk matsalolin kiwon lafiya da masu ciwon sukari ke fuskanta yayin binciken an tattara su a cikin babban tebur. A nan, da kuma cututtuka, da kuma hoto ko bidiyo mai zagaya yanar gizo da sauri, har ma da cututtukan fata. Tare da babban yiwuwa Trazenta ba shine sanadin wannan take hakkin ba. An gwada lafiya da aikin monotherapy na Trazhenta, da haɗe shi da ƙarin wakilai na maganin cututtukan cututtukan fata. A cikin dukkan halaye, ba a gano takamaiman sakamako masu illa ba.

Jiyya tare da Trazhenta ba shi da haɗari kuma cikin sharuddan hypoglycemia. Binciken ya nuna cewa ko da a cikin masu ciwon sukari tare da tsinkaya zuwa saukad da sukari (tsofaffi waɗanda ke fama da cututtukan koda, kiba), yawan yawan hypoglycemia bai wuce 1% ba. Trazhenta ba ya cutar da aikin zuciya da jijiyoyin jini, ba ya haifar da ƙaruwa mai nauyi a hankali, kamar sulfonylureas.

Yawan damuwa

Singleari guda na 600 MG na linagliptin (Allunan 120 na Trazhenta) an yarda da su sosai kuma baya haifar da matsalolin kiwon lafiya. Ba a yi nazarin sakamakon ƙarin allurai akan jikin ba. Dangane da halayen ƙwayar ƙwayar ƙwayar cuta, gwargwado mai tasiri idan an sami yawan zubar da ruwa shine cirewar allunan undigested daga ƙwayar gastrointestinal (lavage na ciki). Hakanan ana gudanar da aikin tiyata da lura da mahimman alamu. Dialysis idan akwai yawan abin sama da ya kamata na Trazhenta ba shi da tasiri.

Contraindications

Allunan tabo ba su amfani:

1. Idan mai ciwon sukari bashi da kwayoyin beta wadanda zasu iya samarda insulin. Dalilin na iya zama nau'in 1 na ciwon sukari ko kamannin ƙwayar cuta.
2. Idan kun kasance rashin lafiyan kowane ɗayan abubuwan kwaya.
3. A cikin tsananin rikitarwar cututtukan zuciya. Magungunan da aka amince da su don maganin ketoacidosis insulin ne na cikin jiki don rage yawan glycemia da saline don gyara bushewar fata. Duk wani shirye-shiryen kwamfutar hannu an soke har sai yanayin ya daidaita.
4. Tare da shayarwa. Linagliptin zai iya shiga cikin madara, ƙwayar narkewa ta yaro, yayi tasiri akan aikin shi na metabolism.
5. A lokacin daukar ciki. Babu wani tabbaci game da yuwuwar shigar linzliptin ta shiga cikin mahaifa.
6. A cikin masu ciwon sukari a karkashin shekara 18. Ba a yi nazarin tasirin jikin yara ba.

Amincewa da Trazhent ya kara sanya hankali ga kiwon lafiya, an ba Trazhent damar nada marassa lafiya wadanda suka girmi shekaru 80, tare da matsanancin ciwo da ciwon koda Amfani da haɗin kai tare da insulin da sulfonylurea na buƙatar sarrafa glucose, saboda zai iya haifar da hypoglycemia.

Abin da analogues za a iya maye gurbin

Trazhenta sabon magani ne, kariyar mallakar patent har yanzu tana kan shi, saboda haka haramun ne a samar da analogues a Rasha tare da jigon iri ɗaya. Dangane da inganci, aminci da kuma tsarin aiki, analogues na rukuni sun kasance kusa da Trazent - masu hana DPP4, ko gliptins. Dukkanin abubuwa daga wannan rukuni ana kiransu ƙare da -gliptin, saboda haka za'a iya rarrabe shi cikin wasu allunan maganin antidi da yawa.

Kwatanta halayen gliptins:

Shirye-shiryen Sulfonylurea (PSM) sune analogues masu sauki na Trazhenta. Hakanan suna haɓaka aikin insulin, amma tsarin tasirin su akan ƙwayoyin beta sun sha bamban. Trazenta yana aiki ne kawai bayan cin abinci. PSM yana tayar da sakin insulin, koda sukari na jini al'ada ne, don haka galibi suna haifar da cutar tarin fuka. Akwai tabbacin cewa PSM mummunan tasiri yana shafi yanayin ƙwayoyin beta. Magungunan Trazhenta a wannan batun ba shi da hadari.

Mafi zamani da marasa lahani na PSM sune glimepiride (Amaryl, Diameride) da glycazide mai tsawo (Diabeton, Glidiab da sauran alamun analogues). Amfani da waɗannan magunguna ƙananan farashi ne, wata na gudanarwa zai biya kusan 150-350 rubles.

Dokokin ajiya da farashi

Shirya Trazhenty farashin 1600-1950 rubles. Za ku iya siyan sa kawai ta hanyar takardar sayan magani. An haɗa da Linagliptin a cikin jerin magunguna masu mahimmanci (Mahimmancin Magunguna masu mahimmanci), don haka idan akwai alamun, masu ciwon sukari da ke rajista tare da endocrinologist zasu iya samun shi kyauta.

Ranar karewa daga Trazenti shekaru 3 ne, yawan zafin jiki a wurin ajiya kada ya wuce digiri 25.

Nasiha